Skip to main content
UniHealth
Find my savings

Doctor search

Karen S Fernandez, MD

Pediatric Medicine · Palo Alto

NPI 1417147174

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Office
1

Offices

1 location

Looking this up.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Fernandez’s office to ask if they take your plan before you enroll.

Medicaid work

$111,839 in 2024

Medicaid paid $111,839 for 1,501 billed services this clinician did in 2024, up to 39 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)281$46,156
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES477$34,655
Service62$9,063
1ST HOSP IP/OBS HIGH 7558$7,281
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter63$5,256
COMPREHENSIVE METABOLIC PANEL256$3,767
Service67$2,285
Service112$2,176
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count45$495
Service12$289
Blood count; blood smear, microscopic examination with manual differential WBC count56$273
Service12$145
Medicaid work by year
20241,5011239$111,839
20231,039935$77,271
20221,1401041$74,931
20211,6191142$111,892
20201,0011033$85,711
20191,5461141$100,500
20182,3591653$133,580
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)253$32,302
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES407$27,869
Service56$8,186
1ST HOSP IP/OBS HIGH 7528$3,562
COMPREHENSIVE METABOLIC PANEL148$2,196
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter14$1,211
Service60$1,211
Service13$443
Blood count; blood smear, microscopic examination with manual differential WBC count60$292

2022

Largest Medicaid services in 2022
Long return visit (40+ min)249$34,228
Service140$20,007
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES176$12,295
COMPREHENSIVE METABOLIC PANEL198$2,932
Service171$2,633
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter15$1,165
Blood count; blood smear, microscopic examination with manual differential WBC count133$646
Service16$546
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count29$317
Vincristine sulfate, 1 mg13$164

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES575$40,360
Long return visit (40+ min)266$37,466
1ST HOSP IP/OBS HIGH 7587$10,929
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter99$7,955
Service57$7,399
COMPREHENSIVE METABOLIC PANEL255$3,688
Service60$2,036
Service71$1,191
Blood count; blood smear, microscopic examination with manual differential WBC count124$580
Vincristine sulfate, 1 mg13$159
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count12$130

2020

Largest Medicaid services in 2020
Long return visit (40+ min)276$37,774
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES446$32,822
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter69$5,968
1ST HOSP IP/OBS HIGH 7533$4,076
Service14$1,449
COMPREHENSIVE METABOLIC PANEL91$1,347
Prolonged service(s) in the outpatient setting requiring direct patient contact beyond the time of the usual service; first hour (List separately in addition to code for outpatient Evaluation and Management or psychotherapy service, except with office or other outpatient services [99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215])14$1,115
Service18$614
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count27$295
Service13$249

2019

Largest Medicaid services in 2019
Long return visit (40+ min)331$44,272
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES251$19,266
Service133$12,716
1ST HOSP IP/OBS HIGH 7561$8,181
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter47$3,970
COMPREHENSIVE METABOLIC PANEL261$3,907
Service102$3,461
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count266$2,931
Service66$1,277
Chemotherapy administration; intravenous, push technique, single or initial substance/drug13$326
Vincristine sulfate, 1 mg15$192

2018

Largest Medicaid services in 2018
Long return visit (40+ min)397$41,748
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES394$29,751
Service251$27,238
1ST HOSP IP/OBS HIGH 7582$9,985
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter76$5,889
COMPREHENSIVE METABOLIC PANEL366$5,475
Service128$4,356
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count371$4,086
Service165$2,877
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)18$647
Chemotherapy administration; intravenous, push technique, single or initial substance/drug17$427
Vincristine sulfate, 1 mg24$300

Money from drug and device companies

$283 in 2025

Industry payments by year
202523None$283
202433None$171
202367None$329
202211None$603
202111None$17
202022None$70
201979None$691

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Y-mAbs TherapeuticsDanyelza$250
2 payments
  • Meals for Danyelza · 2025-09-16 · $125
  • Meals for Danyelza · 2025-04-24 · $125
Day One BiopharmaceuticalsOjemda$33
1 payment
  • Meals for Ojemda · 2025-07-04 · $33
See all 3 published payments
Every published payment
Y-mAbs TherapeuticsMeals · 2025-09-16Danyelza$125
Day One BiopharmaceuticalsMeals · 2025-07-04Ojemda$33
Y-mAbs TherapeuticsMeals · 2025-04-24Danyelza$125
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $171

Payments by company in 2024
Y-mAbs TherapeuticsDanyelza$125
1 payment
  • Meals for Danyelza · 2024-05-23 · $125
Alexion PharmaceuticalsUltomiris$27
1 payment
  • Meals for Ultomiris · 2024-03-21 · $27
Servier PharmaceuticalsAsparlas$19
1 payment
  • Meals for Asparlas · 2024-04-17 · $19

2023: $329

Payments by company in 2023
Y-mAbs TherapeuticsDanyelza$151
2 payments
  • Meals for Danyelza · 2023-12-06 · $26
  • Meals for Danyelza · 2023-01-12 · $125
Fennec PharmaceuticalsPedmark$83
1 payment
  • Meals for Pedmark · 2023-05-23 · $83
Jazz PharmaceuticalsRylaze$33
1 payment
  • Meals for Rylaze · 2023-04-21 · $33
Pharming HealthcareRuconest$24
1 payment
  • Meals for Ruconest · 2023-02-16 · $24
Alexion PharmaceuticalsUltomiris$22
1 payment
  • Meals for Ultomiris · 2023-03-30 · $22
Acrotech BiopharmaBeleodaq$15
1 payment
  • Meals for Beleodaq · 2023-06-14 · $15

2022: $603

Payments by company in 2022
Y-mAbs TherapeuticsNone$603
1 payment
  • Meals · 2022-06-09 · $603

2021: $17

Payments by company in 2021
Novartis PharmaceuticalsAfinitor$17
1 payment
  • Meals for Afinitor · 2021-07-15 · $17

2020: $70

Payments by company in 2020
Servier PharmaceuticalsNone$49
1 payment
  • Meals · 2020-01-09 · $49
Jazz PharmaceuticalsDefitelio$22
1 payment
  • Meals for Defitelio · 2020-11-30 · $22

2019: $691

Payments by company in 2019
Novartis PharmaceuticalsAfinitor$258
3 payments
  • Meals · 2019-08-13 · $122
  • Meals · 2019-08-05 · $120
  • Meals for Afinitor · 2019-02-08 · $16
Shire North American GroupAdvate$122
1 payment
  • Meals for Advate · 2019-06-25 · $122
Servier PharmaceuticalsOncaspar$122
1 payment
  • Meals for Oncaspar · 2019-06-10 · $122
Horizon Therapeutics plcActimmune$114
1 payment
  • Meals for Actimmune · 2019-12-05 · $114
AmgenNplate$37
1 payment
  • Meals for Nplate · 2019-05-01 · $37
Alexion PharmaceuticalsNone$22
1 payment
  • Meals · 2019-08-22 · $22
Emmaus MedicalEndari$15
1 payment
  • Meals for Endari · 2019-01-18 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
JAZZ PHARMACEUTICALS INC. · A Phase 3 Randomized Trial for Patients With De Novo Aml Comparing Standard Therapy Including Gemtuzumab Ozogamicin (Go) To Cpx-351 With Go, and the Addition of the Flt3 Inhibitor Gilteritinib for Patients With Flt3 Mutations · 2024Their institution$10,000
Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2022Their institution$7,000
Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2023Their institution$7,000
PFIZER INC. · Anbl1531 Lorlatinib Arm A Phase 3 Study of 131imetaiodobenzylguanidine 131imibg Or Alk Inhibitor Therapy Added To Intensive Therapy for Children With Newly Diagnosed Highrisk Neuroblastoma Nbl · 2025Their institution$4,800
Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2021Their institution$2,000
Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2025Their institution$1,000
E.R. Squibb & Sons, L.L.C. · Risk Adapted, Response Based Phase 2 Trial of Nivolumab and Brentuximab Vedotin Followed By Brentuximab Vedotin and Bendamustine for Pediatric and Young Adults With Relapsed Or Refractory Cd30 Positive Classic Hodgkin Lymphoma · 2025Their institution$1,000
E.R. Squibb & Sons, L.L.C. · Phase II Pediatric Ph+ All - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added To Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 2023Their institution$1,000
Incyte Corporation · A Phase 2 Study of the Jak1, Jak2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk Crlf2 Rearranged and Or Jak Pathway Mutant Acute Lymphoblastic Leukemia · 2024Their institution$1,000

Professional record

NPI
1417147174
Licence
OH 57.012520
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X); Federal specialty code 2080H0002X (2080H0002X)
Mailing address
725 Welch Rd, Palo Alto, CA, 94304
NPI first listed
2007-07-30
NPI last updated
2025-09-03
NPI record certified
2025-09-03

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 700 Childrens Dr, Columbus, OH, 43205